Association between the LPL-D9N mutation in the lipoprotein lipase gene and plasma lipid traits in myocardial infarction survivors from the ECTIM study

Atherosclerosis

Volumn 122, Issue 1, 1996, Pages 21-28

  Mailly, F ^a   Fisher, R M ^a   Nicaud, V ^b   Luong, L A ^a   Evans, A E ^c   Marques Vidal, P ^d   Luc, G ^e   Arveiler, D ^f   Bard, J M ^g   Poirier, O ^g   Talmud, P J ^a   Humphries, S E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HÔPITAL BROUSSAIS   (France)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d CHU PURPAN   (France)

^e INSTITUT PASTEUR DE LILLE   (France)

^f Lab d'Epidemiol et de S Pub   (France)

^g INSERM   (France)

Author keywords

Case control; ECTIM; Lipoprotein lipase gene mutation; Obesity; Plasma triglycerides

Indexed keywords

LIPOPROTEIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CARRIER; GENE MUTATION; GENETIC PREDISPOSITION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; OBESITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029878072     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05736-6     Document Type: Article

References (29)

1. Jackson RL. Lipoprotein Lipase and hepatic lipase. In: Boyer P (ed). The Enzymes. New York, Academic Press 1983;16:141.
2. Brunzell JD. Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds). The Metabolic Basis of Inherited Disease. New York, Mc-Graw-Hill 1989;1165.
3. Wilson DE, Emi M, Iverius P-H, Hata A, Wu LL, Hillas E. Williams RR, Lalouel JM. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. J Clin Invest 1990;86:735.
4. Ma Y, Liu M-S, Ginzinger D, Frohlich J, Brunzell JD, Hayden MR. Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172→Cys mutation in the lipoprotein lipase gene. J Clin Invest 1993;91:1953.
5. Miesenböck G, Hölzl B, Föger B, Brandstätter E, Paulweber B, Sandhofer F, Patsch JR. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J Clin Invest 1993;91:448.
6. Mailly F, Olivecrona G, Tugrul Y, Reymer PWA, Bruin T, Seed M, Groenemeyer BF, Lansberg PJ, Asplund-Carlson A, Vallance D, Winder AF, Miller GJ, Kastelein JM, Hamsten A, Humphries SE, Talmud PJ. A common variant in the gene for lipoprotein lipase (Asp9→Asn): Functional implications and prevelance in normal and hyperlipidemic subjects. Arterioscler Thromb Vase Biol 1995;15:468.
7. Parra HJ, Arveiler D, Evans AE, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy PH, Luc G, Richard JL, Ducimetiere P, Fruchart JC, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992;12:701.
8. Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the β-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM study. Arterioscler Thromb 1993;13:886.
9. The WHO MONICA Project. A worldwide monitoring system for cardiovascular diseases. World Health Stat Annu 1989;27-149.
10. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Richard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992;359:641.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1989;16:1215.
12. Peacock RE, Hamsten A, Nilsson-Ehle P, Humphries SE. Associations between lipoprotein lipase gene polymorphisms and plasma correlations of lipids, lipoproteins and lipase activities in young myocardial infarction survivors and age-matched healthy individuals from Sweden. Atherosclerosis 1992;97:71.
13. Colton T. Statistics in medicine. Boston, Little, Brown and Co 1974;153.
14. Santamarina-Fojo S. Genetic dyslipidemias: role of lipoprotein lipase and apolipoprotein C-II. Curr Opin Lipid 1992;3:186.
15. Reymer PWA, Gagne E, Groenemeyer BF, Zhang H, Forsyth I, Jansen H, Seidell JC, Krombout D, Lie KE, Kastelein J, Hayden MR. A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nature Genetics 1995;28.
16. Gagne E, Genest Jr J, Zhang H, Clarke LA, Hayden MR. Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. Arterioscler Thromb 1994;14:1250.
17. Fisher RM, Mailly F, Peacock, RE, Hamsten, A, Seed M, Yudkin JS, Beisiegel U, Feussner G, Miller G, Humphries SE, Talmud PJ. Interaction of the lipoprotein lipase asparagine 291→serine mutation with body mass index determines elevated plasma triacylglycerol concentrations: a study in hyperlipidemic subjects, myocardial infarction survivors and healthy adults. J Lipid Res (in press).
18. Fruchart J-C, Bard JM. Lipoprotein particle measurement: an alternative approach to classification of lipid disorders. Curr Opin Lipid 1991;2:362.
19. Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc Natl Acad Sci USA 1991;88:8342.
20. Williams KJ, Petrie KA, Brocia RW, Swenson TL. LPL Modulates Net Secretory Output of Apo B in vitro. J Clin Invest 1991;88:1300.
21. Richelsen B, Pedersen SB, Moller-Pedersen T, Schmitz O, Moller N, Borglum, JD. Lipoprotein lipase actvity in muscle tissue influenced by fatness, fat distribution and insulin in obese females. Eur J Clin Invest 1993;23:226.
22. Semenkovich CF, Wims M, Noe L, Etienne J, Chan L. Insulin regulation of lipoprotein lipase activity in 3T3-L1 adipocytes is mediated at posttranscriptional and post-translational levels. J Biol Chem 1989;264:9030.
23. Taskinen M-R. LPL in hypertriglyceridemias. In: Borensztajn J (ed). Lipoprotein Lipase. Chicago, Everer 1987;201.
24. Goldberg AP, Chait A, Brunzell JD. Postprandial adipose tissue LPL activity in primary hypertriglyceridemia. Metabolism 1980;29:223.
25. Schwartz RS, Brunzell JD. Increase of adipose tissue lipoprotein lipase activity and weight loss. Metabolism 1981;1425.
26. Karpe F, Olivecrona T, Walldius G, Hamsten A. LPL in plasma after an oral fat load: relation to free fatty acids. J Lipid Res 1992;33:975.
27. Ma Y, Ooi, TC, Liu M-S, Shang H, McPherson R, Edwards AL, Forsythe IJ, Frohlich J, Brunzell JD, Hayden MR. High frequency of mutations in the human lipoprotein lipase gene in pregnancy-induced chylomicronemia: possible association with apolipoprotein E2 isoform. J Lipid Res 1994;35:1066.
28. Carlson LA, Bottiger LE. Risk factors for ischaemic heart disease in men and women: results of the 19-year follow-up of the Stockholm Prospective Study. Acta Med Scand 1985;218:207.
29. Bainton D, Miller NE, Bolton CH, Yarnell JW, Sweet-man PM, Baker IA, Lewis B, Elwood PC. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 1992;68:60.